An antibody comprised of both mouse and human antibody components, usually a 30/70 percent split, respectively.
A recombinant antibody that combines characteristics of antibodies from two different sources (see Humanized antibody).
a molecule in which different portions are derived from different animal species, for example, those having a variable region derived from a murine mAb and a container region derived from human immunoglobulin
a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region
An antibody that is made of segments of both mouse and human antibodies, usually a 30/70 percent split, respectively.
Refers to the fact that the antibody is made of both mouse and human antibodies, usually a 30/70 percent split, respectively.
A chimeric antibody consists of human protein sequences fused with murine protein sequences, the latter often containing the specific binding site Clinical research The research phases concerning human subjects. Phase I studies are principally designed to examine the safety of a new medication and to begin to understand how the drug will work in humans. Phase II studies are principally designed to evaluate the therapeutic effect of a new drug in patients who suffer from the targeted disease, to establish optimum dose level, and to confirm the safety profile established in earlier Phase I trials. Phase III trials are principally designed to confirm the therapeutic effect and absence of negative side effects in a larger patient population. Furthermore, to demonstrate the potential advantages of the new therapy over other therapies that are already on the market.